article
Tackling the organ shortage through vascular bioengineering
Frontier Bio’s vascular bioengineering research connects tissue modelling with graft development to advance regenerative medicine and drug discovery.
List view / Grid view
Analysis
article
Transforming central labs with automation and AI: setting new standards for modern trials
Demands on central laboratories are consistently increasing, heightening the challenge to deliver operational excellence and the highest standard of scientific integrity with both speed and agility. ICON Laboratories is transforming the way we leverage data and intelligent operational models to meet evolving trial needs.
article
Deep data not big data
Bigger isn’t always better. In drug discovery, Dr Michael Ritchie argues that the future belongs not to those with the most data, but to those who understand its biological depth.
article
AI and the future of biomarker analysis in early R&D
AI is transforming biomarker analysis in early drug discovery, revealing hidden biological patterns that improve target discovery, patient selection and trial design for more precise and predictive R&D.
article
Why first-void urine could potentially change the future of HPV screening
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
article
Beyond weight loss: the gap in current drug development for obesity
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
news
RNA folding: new model could change future drug design
A Japanese research team has simulated how RNA molecules fold, using cutting-edge computational tools to model complex structures with accuracy – a breakthrough that could accelerate the development of RNA-based medicines and therapies.
article
Inside ELRIG Drug Discovery 2025: automation, AI and human-relevant models
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
article
When chemistry corrects biology: the deuterated return of a MET inhibitor
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
article
From wild fungi to faster drug discovery
Nature’s pharmacy has yielded half of today’s medicines, yet most of its potential remains untapped. AI is now changing how quickly new therapies can be found.
news
Pulmonary fibrosis: new drug slows and reverses lung scarring
Researchers have identified a key cellular mechanism that drives pulmonary fibrosis and successfully blocked it in mice, reducing lung scarring.
news
Enzyme PapB could boost diabetes and obesity peptide drugs
Researchers have discovered an enzyme, PapB, that can ‘tie off’ therapeutic peptides into stable rings, which could help improve GLP-1 drugs for diabetes and obesity – making them more effective and longer lasting.
article
How real-world data is accelerating drug discovery
Vish Srivastava considers the benefits of expanding the role of real-world data in drug discovery to provide improved therapies, faster and with greater success.
article
SPNS1 mutations reveal new lysosomal lipid recycling pathway
Scientists have linked rare mutations in SPNS1 to a previously unknown lipid recycling pathway in lysosomes, revealing how faulty fat processing can trigger muscle and liver disease.
article
Eye movements as objective biomarkers: accelerating CNS drug development
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.
